Get the Stockscreener App
8.79
3.30%
-0.30
After Hours:
8.65
-0.14
-1.59%
Vir Biotechnology Inc stock is traded at $8.79, with a volume of 1.71M.
It is down -3.30% in the last 24 hours and down -15.97% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$9.09
Open:
$8.96
24h Volume:
1.71M
Relative Volume:
0.54
Market Cap:
$1.48B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-2.7782
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
-3.62%
1M Performance:
-15.97%
6M Performance:
+56.13%
1Y Performance:
+93.19%
1-Day Range:
$8.64
$8.98
1-Week Range:
$8.64
$9.645
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.79 | 1.53B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
SoftBank group reports 10.95M-share stake in Vir Biotechnology (VIR) - Stock Titan
How Marianne De Backer saved Vir Biotechnology after flu drug failureSan Francisco Business Times - The Business Journals
Vanguard Group Inc. Reduces Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc.Common Stock (NQ: VIR - FinancialContent
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com
Vir Biotech May 2026 slides: CHD combo hits 88% viral suppression - Investing.com UK
Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright - MarketBeat
TradingKey - TradingKey
Vir Biotechnology, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next - simplywall.st
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts - Yahoo Finance
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Vir (VIR) Q1 2026 Earnings Call Transcript - AOL.com
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Vir Biotechnology (VIR) Eps Diluted (TTM) - Zacks Investment Research
Vir Biotechnology Signals Momentum in Latest Earnings Call - TipRanks
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30 - Moomoo
Vir Biotechnology Q1 2026 earnings preview - MSN
Evercore Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Vir Biotechnology anticipates VIR-5500 Phase III start in 2027 while expecting cash runway into 2H 2028 - MSN
Moderna, Vir among early 2026 top infectious disease gainers - BioWorld News
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
Vir Biotechnology 1Q 2026: Revenue ($29K), Net income ($125.7M), EPS ($0.85) — 10-Q Summary - TradingView
Vir Biotechnology Q1 Earnings Call Highlights - MarketBeat
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results - BioSpace
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com India
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Astellas collaboration brings $315M to Vir Biotechnology (VIR) - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Posts Earnings Results - MarketBeat
Vir Biotechnology schedules Q1 2026 earnings call for 4:30 p.m. ET - Traders Union
Vir Biotechnology Q1 net loss widens - TradingView
Vir Biotechnology (Nasdaq: VIR) extends cash runway into 2H 2028 - Stock Titan
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 75c, offers outlook - StreetInsider
Vir Biotech investors brace for earnings as losses shrink By Investing.com - Investing.com Nigeria
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference - PharmiWeb.com
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology schedules CEO fireside chat at major healthcare event - Traders Union
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
Vir Biotechnology director Vicki Sato sells $221,025 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology director Vicki Sato sells $221,025 in stock - Investing.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):